Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy [Phase 4]

View source ↗

Summary

Phase 4 trial assessing ixazomib with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma after initial proteasome inhibitor therapy; study c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• And or Refractory Multiple Myeloma

Drugs mentioned

• DEXAMETHASONE (Dexamethasone)
• Lenalidomide (lenalidomide)
• ixazomib (ixazomib)

Snippet

Sponsor: Takeda | Conditions: Relapsed and/or Refractory Multiple Myeloma | Phase 4 | Status: COMPLETED | Results posted: 2022-08-22